Biosimilars – How similar must they be?
28th April 2011
Category: Biosimilars
Tags: Biosimilar mAbs, Biosimilar market
By: Dr Daniel Galbraith, CSO,
The hype over the market for biosimilars remains buoyant; research indicates that the market is likely to be worth almost USD$20 Billion by 2014. This increase is in some part driven by the major Asian players who have well over one third of the market. This push is in many ways due to the strong More
Coping with New Virus Risks in the Manufacture of Biologics
14th April 2011
Category: Biosafety
Tags: Biologics, PCR testing, Virus
By: Dr Daniel Galbraith, CSO,
In June 2009 a new virus was added to the growing list of agents found contaminating Chinese Hamster Ovary cells used in the manufacture of Biologics. Genzyme reported a contamination of CHO bioreactor with Vesivirus (subsequently named 2117); this was the third time such infection of a bioreactor had occurred in Genzyme. This virus which More